ArticleNature2022
Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Abstract readPublished Erratum
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development of a recombinant single-cycle influenza viral vector as an intranasal vaccine against SARS-CoV-2.Scientific reports · 2026Article
- Development of a Recombinant Single-Cycle Influenza Viral Vector as an Intranasal Vaccine against SARS-CoV-2 and SARS-like Betacoronaviruses.bioRxiv : the preprint server for biology · 2025Article
- Licorice-saponin A3 is a broad-spectrum inhibitor for COVID-19 by targeting viral spike and anti-inflammation.Journal of pharmaceutical analysis · 2023Article
Corrections and comments
- Erratum for
Authors and funding
41 authors.
Dami A Collier *Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.ORCID http://orcid.org/0000-0001-5446-4423
Anna De Marco *Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Isabella A T M Ferreira *Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.
Bo Meng *Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.
Rawlings P Datir *Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.ORCID http://orcid.org/0000-0003-0521-2144
Alexandra C WallsDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Steven A KempCambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.
Jessica BassiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Dora PintoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Chiara Silacci-FregniHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Siro BianchiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-5100-8905
M Alejandra TortoriciDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2260-2577
John BowenDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Katja CulapHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-0956-0018
Stefano JaconiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Elisabetta CameroniHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Gyorgy SnellVir Biotechnology, San Francisco, CA, USA.
Matteo S PizzutoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Alessandra Franzetti PellandaClinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Christian GarzoniClinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Agostino RivaDivision of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy.ORCID http://orcid.org/0000-0003-3171-3049
CITIID-NIHR BioResource COVID-19 Collaboration
Anne ElmerNIHR Cambridge Clinical Research Facility, Cambridge, UK.
Nathalie KingstonNIHR Bioresource, Cambridge, UK.
Barbara GravesNIHR Bioresource, Cambridge, UK.
Laura E McCoyDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0001-9503-7946
Kenneth G C SmithCambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.ORCID http://orcid.org/0000-0003-3829-4326
John R BradleyDepartment of Medicine, University of Cambridge, Cambridge, UK.
Nigel TempertonUniversity of Kent, Canturbury, UK.
Lourdes Ceron-GutierrezDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.
Gabriela Barcenas-MoralesDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.
COVID-19 Genomics UK (COG-UK) Consortium
William HarveyInstitute of Biodiversity, University of Glasgow, Glasgow, UK.
Herbert W VirginVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8580-7628
Antonio LanzavecchiaHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-3041-7240
Luca PiccoliHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-1085-6502
Rainer DoffingerDepartment of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0002-9841-3617
Mark WillsDepartment of Medicine, University of Cambridge, Cambridge, UK.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6019-8675
Davide CortiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.ORCID http://orcid.org/0000-0002-5797-1364
Ravindra K GuptaCambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. rkg20@cam.ac.uk.ORCID http://orcid.org/0000-0001-9751-1808
Funding
Medical Research Council MR/R008698/1
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.